Filing and reporting period
The supplied filing is Sigma Labs, Inc.’s Form 10-K for the fiscal year ended December 31, 2012, filed April 16, 2013. It is not a Nexttrip, Inc. filing. It reports full-year results; the filing text does not provide separate fourth-quarter financial statements or results.
Sigma Labs develops manufacturing quality-control and materials technologies, including PrintRite3D for additive manufacturing, biomedical implant surface treatments, and munitions technologies. It also generated revenue from engineering and scientific consulting. Sumner and La Mancha were acquired on December 31, 2011 for 35 million shares; Sumner contributed consulting operations, while La Mancha was inactive.
Financial performance and position
| Metric | FY 2012 | FY 2011 | Change / context |
|---|---|---|---|
| Revenue | $986,499 | $797,354 | Up 23.7%; primarily consulting revenue |
| Cost of service revenue | $554,828 | $412,396 | Increased faster than revenue |
| Gross profit / margin | $431,671 / 43.8% | $384,958 / 48.3% | Gross margin declined about 4.5 percentage points |
| General and administrative | $649,926 | $426,519 | Increased about 52% |
| Payroll expense | $326,242 | $650,181 | Decreased substantially |
| Non-cash stock compensation | $141,500 | $219,500 | Decreased |
| Net loss | $(685,566) | $(910,129) | Loss narrowed about 24.7% |
| Operating cash flow | $(481,924) | $(575,469) | Cash used in operations remained significant |
| Cash at year-end | $150,071 | $653,113 | Down $503,042 |
| Working capital | $315,574 | $770,579 | Surplus declined |
| Total assets | $691,712 | $1,276,196 | Declined |
| Total liabilities | $133,942 | $174,702 | All reported as current; no debt balance reported |
Cash used in investing activities was $21,460 in 2012. Financing provided only $342 in 2012; the prior-year figure included $1,011,765 of net proceeds from a stock offering. No income-tax expense was recorded. Basic and diluted loss per share was shown as $(0) after rounding.
Changes, outlook, and material developments
- Revenue grew, but it remained service-based: the company reported no sales of its core technologies through year-end 2012. The 2011 comparison excludes Sumner and La Mancha’s pre-acquisition results, limiting comparability.
- Management expected to fund operations through consulting contracts and additional securities sales until technology commercialization. At March 31, 2013, the company cited potential 2013 contract revenue of up to $45,363 for B6 Sigma and $388,298 for Sumner; these were expectations, not guaranteed revenue. La Mancha had no active contracts.
- Management targeted commercialization of IPQA and munitions technologies in 2013 and continued development of implant technology. These plans were uncertain; the filing gives no revenue guidance or assurance of commercialization.
- On April 11, 2013, after year-end, Sigma Labs granted Allotrope Sciences an exclusive five-year license to market ARMS and BAM munitions technologies to government customers. The agreement provides specified license fees and conditional royalties; future sales and royalty revenue were not established in the filing.
- The company reported an award of a U.S. patent for IPQA and two U.S. patents related to munitions, alongside further patent applications. Management described preliminary implant testing results, including an apparent reduction in healing time, but these were early-stage findings.
Risks, contingencies, and unusual items
- The auditor issued an unqualified opinion on the financial statements but highlighted substantial doubt about the company’s ability to continue as a going concern, citing recurring losses and the absence of profitable operations. The company said continued operations depend on profitability and/or outside funding.
- Customer concentration was high: three customers accounted for 53%, 26%, and 19% of 2012 revenue. The filing identifies major consulting clients elsewhere, but the concentration table labels customers only A–E.
- The company had no credit facility and stated that future liquidity depended on consulting revenue and securities offerings. Additional equity financing could dilute shareholders.
- Other principal risks include early-stage technology and commercialization uncertainty, competition from better-resourced firms, dependence on government contracts and regulatory compliance, fixed-price contract cost overruns, intellectual-property risks, and limited financial and management resources.
- The stock was thinly and sporadically traded on the OTC Bulletin Board. No dividends were anticipated. The filing also reports 30 million shares reserved under a 2013 equity plan approved by the board but not yet by shareholders.
- Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2012. The auditor did not attest to internal-control effectiveness.
Investor verification priorities
- Confirm the issuer and filing identity: the supplied document is for Sigma Labs, Inc., not Nexttrip, Inc.
- Review the audited statements and going-concern disclosure, and assess cash runway against operating cash use and the need for external financing.
- Validate the reported consulting backlog and expected 2013 contract revenue, including whether contracts were awarded, funded, and performed.
- Track actual PrintRite3D, implant, and munitions commercialization, including the Allotrope license fees, sales thresholds, and royalties.
- Investigate customer concentration, especially the customers representing 53%, 26%, and 19% of 2012 revenue, and whether that dependence persists.
- Reconcile share counts and potential dilution, including outstanding shares, restricted stock, warrants, and the 2013 equity incentive plan.